Archives
-
MK-4827 Workflow for PARP Inhibition Studies
2026-08-27
Build sharper DNA damage repair inhibition assays with MK-4827 (Niraparib), from BRCA-genotype profiling through sequential cisplatin and maintenance designs. This workflow also shows how to troubleshoot solubility, exposure timing, and PARP pharmacodynamic readouts for cancer research.
-
3-Deazaadenosine: From Methylation to Translation
2026-08-26
A translational framework for using 3-Deazaadenosine as an S-adenosylhomocysteine hydrolase inhibitor in methylation, inflammation, and preclinical antiviral research—while separating target-specific evidence from broader metabolic perturbation.
-
Lipo3K Transfection Reagent: Translational Strategy
2026-08-26
A thought-leadership guide to using Lipo3K Transfection Reagent as a mechanistically informed tool for studying membrane biology, drug resistance, gene expression, and RNA interference in challenging cell models.
-
Talin1–Piezo1–YAP Signaling in Atherosclerosis
2026-08-25
A 2026 study identifies Talin1 as a mechanistic link between Piezo1-mediated calcium entry, YAP activity, and inflammatory activation in endothelial cells. Its combined mouse and cell models suggest that Talin1 is more than a plaque-associated marker and may represent a focused target for studying disturbed-flow inflammation in atherosclerosis.
-
Nitroaromatic Nannocystin Targets AKT1 in Colorectal Cancer
2026-08-25
Zhang and colleagues developed a nitroaromatic nannocystin that showed nanomolar activity against colorectal cancer models and suppressed tumor growth in a patient-derived xenograft model. By combining synthesis, organoids, RNA sequencing, molecular docking, and cellular thermal shift analysis, the study connected the compound’s activity to AKT1 while also identifying apoptosis, cell-cycle disruption, and senescence as relevant cellular outcomes.
-
Sphingosine-1-phosphate: S1P Signaling Guide
2026-08-24
Sphingosine-1-phosphate (S1P) is an endogenous bioactive lipid that links GPCR signaling with cell proliferation and survival signaling, vascular maturation, and apoptosis. Its effects depend on receptor subtype and biological context, as shown by S1PR1-associated vascular signaling and S1PR3-associated neuronal apoptosis after experimental intracerebral hemorrhage.
-
Bafilomycin C1 in High-Content Phenotypic Screens
2026-08-24
Bafilomycin C1 is a vacuolar H+-ATPases inhibitor that can do more than block autophagic flux. This article presents a mechanistic framework for using lysosomal perturbation to interpret high-content and deep-learning phenotypic assays, including iPSC-cardiomyocyte models.
-
Dye Models for Small Tissue Biopsies in Pathology
2026-08-23
The reference study evaluates five dyes as visibility aids for 0.2–0.3 cm tissue samples during surgical pathology preparation. Merbromin, hematoxylin, and alcian blue improved sample visibility, but hematoxylin offered the most favorable balance of visibility, safety, and compatibility with routine slide interpretation.
-
G4–STAT1 Disruption and Olaparib Synergy in Cancer
2026-08-22
A 2026 Nucleic Acids Research study identifies the BLM promoter G-quadruplex as a regulatory platform that recruits phosphorylated STAT1 and activates BLM expression. The work further shows that berberine or coptisine can disrupt this interaction and cooperate with olaparib to increase DNA damage and colon cancer cell death, providing a mechanistic rationale for combining G4-targeting compounds with PARP inhibition.
-
NF 449 and Platelet P2 Receptor Inhibition
2026-08-22
The reference study established NF 449 as a pharmacological tool for separating platelet P2X1 signaling from P2Y1 and P2Y12 responses. Its combination of receptor-level assays, platelet aggregation experiments, and mouse thrombosis models showed that selective P2X1 inhibition can reduce thrombus-related platelet activation without significantly prolonging bleeding time under the tested conditions.
-
Fe3O4@ZIF-8 for Jaw Osteomyelitis
2026-08-21
The reference study develops Fe3O4@ZIF-8 core–shell nanoparticles that combine pH-responsive Zn2+ release for antibacterial action with magnetically supported bone regeneration. Its significance lies in addressing persistent infection and infected bone defects within one biomaterial platform, while also identifying bacterial membrane disruption and heat-shock-response inhibition as complementary antibacterial mechanisms.
-
BMN 673 (Talazoparib) Experimental Workflow
2026-08-20
BMN 673 (Talazoparib) combines subnanomolar PARP1/2 inhibition with strong PARP-DNA complex trapping, making it a useful probe for DNA repair deficiency targeting. This guide translates the mechanism into practical workflows for homologous recombination-deficient models, HCC spliceosome studies, and small cell lung cancer research, with controls and troubleshooting built in.
-
Age-Related CMA Decline Drives Skeletal Myopathy
2026-08-20
The reference study establishes chaperone-mediated autophagy (CMA) as an active regulator of skeletal muscle maintenance rather than a passive lysosomal pathway. Using reporter, genetic, proteomic, physiological, and human-tissue approaches, it connects age-related CMA loss to SERCA turnover, calcium dysregulation, muscle weakness, and progressive myopathy.
-
SR 11302: AP-1 Transcription Factor Inhibitor
2026-08-19
SR 11302 is an AP-1 transcription factor inhibitor that suppresses AP-1 activity without activating RAR or RXR receptors. Product data support selective antiproliferative effects in several cancer cell models and reduced carcinogen-induced papilloma formation in AP-1-luciferase transgenic mice.
-
Fluorinated CXCR4 Inhibitor A1 in Colorectal Cancer
2026-08-19
Khorramdelazad et al. evaluated A1, a fluorinated CXCR4 inhibitor, using molecular dynamics, CT-26 cell assays, and a BALB/c colorectal cancer model. A1 showed stronger computational binding, reduced tumor-cell proliferation and migration, altered immunosuppressive tumor-microenvironment features, and outperformed AMD3100 in several in vivo endpoints, while remaining a preclinical candidate requiring further validation.